VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Thursday, January 8, 2026

Stock Comparison

Accenture plc vs Boston Scientific Corporation

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Accenture plc

ACN · New York Stock Exchange

Market cap (USD)$164.5B
Gross margin (TTM)31.9%
Operating margin (TTM)14.8%
Net margin (TTM)10.8%
SectorTechnology
IndustryInformation Technology Services
CountryIE
Data as of2025-12-30
Moat score
66/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Accenture plc's moat claims, evidence, and risks.

View ACN analysis

Boston Scientific Corporation

BSX · New York Stock Exchange

Market cap (USD)$141.5B
Gross margin (TTM)65.1%
Operating margin (TTM)17.3%
Net margin (TTM)14.4%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2026-01-04
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Boston Scientific Corporation's moat claims, evidence, and risks.

View BSX analysis

Comparison highlights

  • Moat score gap: Accenture plc leads (66 / 100 vs 65 / 100 for Boston Scientific Corporation).
  • Segment focus: Accenture plc has 2 segments (50.4% in Consulting); Boston Scientific Corporation has 5 segments (49.8% in Cardiology).
  • Primary market structure: Competitive vs Oligopoly. Pricing power: n/a vs Moderate.
  • Moat breadth: Accenture plc has 7 moat types across 3 domains; Boston Scientific Corporation has 6 across 3.

Primary market context

Accenture plc

Consulting

Market

Enterprise consulting (strategy, management, technology consulting and technology integration consulting)

Geography

Global

Customer

Enterprises and public sector organizations

Role

Advisor and systems integrator / implementation partner

Revenue share

50.4%

Boston Scientific Corporation

Cardiology

Market

Cardiology devices (interventional cardiology, structural heart, electrophysiology, cardiac rhythm management and remote monitoring)

Geography

Global

Customer

Hospitals/cath labs/EP labs and specialty clinics (cardiologists, electrophysiologists)

Role

Medical device OEM / implantables + procedure devices + service-enabled monitoring

Revenue share

49.8%

Side-by-side metrics

Accenture plc
Boston Scientific Corporation
Ticker / Exchange
ACN - New York Stock Exchange
BSX - New York Stock Exchange
Market cap (USD)
$164.5B
$141.5B
Gross margin (TTM)
31.9%
65.1%
Operating margin (TTM)
14.8%
17.3%
Net margin (TTM)
10.8%
14.4%
Sector
Technology
Healthcare
Industry
Information Technology Services
Medical - Devices
HQ country
IE
US
Primary segment
Consulting
Cardiology
Market structure
Competitive
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
n/a
Moderate
Moat score
66 / 100
65 / 100
Moat domains
Demand, Supply, Network
Demand, Legal, Supply
Last update
2025-12-30
2026-01-04

Moat coverage

Shared moat types

Procurement Inertia

Accenture plc strengths

Brand TrustSuite BundlingService Field NetworkLong Term ContractsSwitching Costs GeneralEcosystem Complements

Boston Scientific Corporation strengths

Installed Base ConsumablesTraining Org Change CostsRegulated Standards PipeReputation ReviewsDistribution Control

Segment mix

Accenture plc segments

Full profile >

Consulting

Competitive

50.4%

Managed Services

Oligopoly

49.6%

Boston Scientific Corporation segments

Full profile >

Endoscopy

Oligopoly

16%

Urology

Competitive

13.1%

Neuromodulation

Oligopoly

6.6%

Cardiology

Oligopoly

49.8%

Peripheral Interventions

Competitive

14.4%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.